Psoriasis comorbidities.
Psoriasis is a chronic and debilitating inflammatory disease associated with serious comorbidities. Psoriasis can have a significant impact on a patient's quality of life and is associated with loss of productivity, depression, and an increased prevalence of malignancy. Emerging comorbidities of psoriasis include cardiovascular disease and metabolic syndrome. Psoriasis patients have an increased prevalence of the core components of metabolic syndrome, including obesity, dyslipidemia, and insulin resistance. The relationship between psoriasis and comorbidities such as metabolic syndrome and cardiovascular disease is likely linked to the underlying chronic inflammatory nature of psoriasis. The molecular mechanisms involved in psoriasis-associated dysregulation of metabolic function are believed to be due, in large part, to the action of increased levels of proinflammatory factors, such as tumor necrosis factor-alpha, that are central to the pathogenesis of psoriasis. Recent studies investigating the effects of tumor necrosis factor antagonists on the treatment of cardiovascular disease and metabolic syndrome support this concept.
Gottlieb
Alice B
AB
Tufts-New England Medical Center, Boston, MA 02111-1533, USA. agottlieb@tufts-nemc.org
Chao
Chun
C
Dann
Frank
F
D015535:Arthritis, Psoriatic / Q000150:complications; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology; D015897:Comorbidity; D003863:Depression / Q000150:complications; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000453:epidemiology; D009369:Neoplasms / Q000150:complications; D011565:Psoriasis / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D011788:Quality of Life; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha